



A Study of Safety and Effectiveness of Intra Venous Iron Sucrose Therapy in Pregnant Women Suffering From Moderate to Severe Iron Deficiency Anaemia Disease

Heena Rajput^{a#}, Kinnari Amin^{a#}, Bhamini Kadikar^{a#}, Nilesh Shah^{a≡},
Kalgi Shah^{b*o} and Ishan Shah^{a†}

^a Department of Obstetrics and Gynaecology, Nootan Medical College & Research Centre, Visnagar, Gujarat, India.

^b Department of Medicine, Nootan Medical College & Research Centre, Visnagar, Gujarat, India.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JAMMR/2022/v34i131249

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/82386>

Original Research Article

Received 09 November 2021

Accepted 12 January 2022

Published 15 January 2022

ABSTRACT

Aims & Objectives: To determine the effectiveness and safety of IV Iron sucrose therapy in antenatal women with moderate to severe Iron deficiency anaemia.

Methodology: It is a retrospective study with secondary data analysis. We have analyzed the data collected from January 2019 to December 2019 at the Nootan general hospital, Visnagar, Gujarat, India. Analysis of antenatal women with moderate to severe anaemia (Hb 6 to 8gm%) in the second trimester and early third trimester (20 to 34 weeks of gestation) are done during their routine antenatal care who were prescribed Intravenous Iron sucrose in a standard-dose of 1000 mg given as 200 mg on alternate days after confirming the iron deficiency anaemia. Effectiveness of the therapy has been studied by comparing the Hb level at the point baseline where start of the treatment and 4 week or more after the last treatment was given (endline). The safety profile of the

Assistant Professor;

≡ Professor & Head of Department;

o Associate Professor & HOU;

† Lecturer & Research Scholar;

*Corresponding author: E-mail: kalgish86@gmail.com;

therapy has been assessed by noticing any adverse drug reaction after starting the infusion.

Results: Mean increase in Hb in cases of moderate & severe anaemia was 3.69 g/dl (1.19) and 3.91 (1.25) g/dl respectively. Overall rise of Haemoglobin was 3.79 g/dl (1.1)(95% CL: 3.35, 4.23). Calculated p value in our study is < 0.001 which is statistically significant.

Conclusion: The mean rise in Haemoglobin level in our study was 3.79 g/dL when 1000 mg of Intra venous iron sucrose was given to antenatal women with moderate as well as severe anaemia is concerned. The magnitude of the anaemia difference is directly proportional rise of haemoglobin level. The amount of haemoglobin rise is seen more in severe anaemic antenatal patients compared with moderate antenatal patients. We recommend that Intravenous iron sucrose therapy should be included as second choice for severely anaemic pregnant women where situation is not supportive for blood transfusion or patient is noncompliant.

Keywords: Iron deficiency anemia; antenatal women; Iron sucrose complex; parental Iron therapy.

1. INTRODUCTION

Iron deficiency and its after-effects continue to be prevalent in epidemic proportions despite major health changes over the past century [1]. Estimates from WHO report suggests that more than 50% of antenatal women in developing countries are anemic [2]. Prevalence of anaemia among pregnant women in India is 57% [3] and Iron deficiency anaemia is responsible for 95% of anaemia during pregnancy [4]. Anaemia contributes about 50 % ration in maternal mortality in South Asian countries; India contributes to about 80 per cent of this mortality ratio [5]. Although the adverse consequences on maternal and child health are well known, it continues to be sub-optimally managed. In the current article we focus on management of Iron deficiency anaemia in pregnancy as it is one of the most commonly spread of all nutritional deficiencies in Pregnancy.

The standard protocol for treatment of severe iron deficiency anaemia in antenatal patients came in emergency in majority of the institutions is oral iron with blood transfusion. Iron in oral route takes long time to correct the anaemia and leads to significant gastrointestinal side effects on larger doses. Transfusion of blood also has its own side effects like mismatch blood transfusion, transmission of deadly viral infections like Cytomegalo virus, HIV, Hepatitis and anaphylactic reactions. So there is a need of safe and effective alternative like injectable iron preparation which can be administered in short period with good safety profile. Iron dextran, the first parenteral iron used for anaemia has become obsolete due to its higher side effects and anaphylactic reactions effects.

Iron sucrose injection has proved its safety and efficacy worldwide with multiple clinical trials and

meta-analysis. Bio availability of Iron sucrose is very fast after administration besides being safe, convenient and more effective than intramuscular iron therapy in the treatment of iron deficiency anaemia during pregnancy [6]. This study was therefore to evaluate the effectiveness and safety of intravenous Iron sucrose therapy in antenatal women with Iron deficiency anaemia.

2. MATERIALS AND METHODS

It is a retrospective study with secondary data analysis in which we have analyzed the data collected from January 2019 to December 2019 at the Nootan general hospital, Visnagar, Gujarat, India, of antenatal women with moderate to severe anaemia (Hb 6 to 8gm%) in the second and early third trimester (20 to 34 weeks of gestation) during routine antenatal care who were prescribed Intravenous Iron sucrose in a standard-dose of 1000 mg given as 200 mg on alternate days after confirming the iron deficiency anaemia.

Effectiveness of the therapy has been studied by comparing the Hb level at the point baseline where start of the treatment and 4 weeks or more after the last treatment was given (endline). The safety profile of the therapy has been assessed by noticing any adverse drug reaction after starting the infusion.

Counselling of the all subjects was done about pros and cons of use of injectable iron sucrose. All consented pregnant women were prescribed a total equal dose of 1000 mg of Intra venous iron sucrose. In each subjects we administer total 1000 mg of intravenous iron sucrose in five divided doses of 200 mg in 100 ml of normal saline for the period of 30-40 mins atleast. These doses were given to antenatal patients on alternate days. To prevent any reaction or

anaphylactic effects first dose was given to any patients very slowly at the speed of 60 ml/hour for initial 5 to 10 minutes. In remaining doses infusion was given at 100-125 ml/hour. There is no requirement of any test dose in intravenous iron sucrose therapy. The five doses were given continuously with one day off. Advice was given to each and every antenatal mother not to take any oral iron preparation during this therapy period. All participant antenatal women were advised to come for follow-up measurement of Haemoglobin level and other routine antenatal check up any time after 4 weeks of the last infusion of Intravenous iron sucrose.

We have used same lot and batch of IVIS for every patient so bias can be minimised. In hemocue machine, 2 lots in same batch were used.

2.1 Study Design

2.1.1 Type

Retrospective analytical study.

2.1.2 Location

Nootan General Hospital, Visnagar, Gujarat, India.

2.1.3 Duration

1 year.

2.2 Sample Size

Total 110 consented antenatal subjects were analysed retrospectively from the clinical data available in the medical records department of the institution after taking permission from the concerned authority.

2.3 Inclusion Criteria

All the pregnant women with 20 to 34 weeks of gestation and Hb of 6 to 8gm% who received Intravenous iron sucrose therapy between January to December 2019.

2.4 Statistical Analysis

Microsoft excel sheet (2016) was used for entering the data and descriptive analysis was done. Statistical significance of the study has been calculated by T test (P value). Data were analysed on Haemoglobin level at pre-infusion

time, and at 4-week or later after the last Intravenous iron sucrose dose post infusion time. Analysis of data was done by MedCalc version 9.2.0.1. Descriptive analysis of the change in Haemoglobin level is presented as mean (standard deviation [SD]) and 95% confidence interval (CI).

3. RESULTS

Intravenous iron sucrose was infused in total 110 subjects. Pre infusion Haemoglobin level and after infusion haemoglobin level for all 110 subjects were available for statistical analysis. At pre infusion level, the proportion of moderate anaemia was 80% and the proportion of severe anaemia was 20%, [Table 1]. The number of antenatal patients suffering from severe anaemia decreased from 22 to 2 (90.9% reduction). Similarly, the reduction in moderate anaemia in antenatal women was 82.9% [Table 1]. Overall, the mean (SD) Haemoglobin level rise from 7.2 g/dl (0.7) at pre infusion level, to 10.99 g/dl (1.2) at endline, with a mean increase of 3.79 g/dl (1.1). There were no serious or major adverse reactions reported between the observation period.

Overall, 28.18 % antenatal women reached to normal haemoglobin level (Haemoglobin >11 g/dl) at the time of endline measurement. The pregnant women who achieved normal Haemoglobin level were 34.09 % in moderate anaemia. While 22.7 % antenatal women with severe anaemia achieved normal haemoglobin level. Although only 28.18 % pregnant women achieved normal Haemoglobin level, a large proportion of the moderate to severe anaemic antenatal patients (70 %) changed to a less severe category of anaemia during their current pregnancy time.

Mean increase in Hb in cases of moderate & severe anaemia was 3.69 g/dl (1.2) and 3.91 (1.25) g/dl respectively. Overall rise in Hb was 3.79 g/dl (1.1)(95% CL: 3.35, 4.23). p value which was calculated in our study is < 0.001 which is statistically significant.

4. DISCUSSION

In this study, the difference in Haemoglobin level 4 week after last dose of Intravenous iron sucrose infusion was measured. The mean rise in Haemoglobin level was 3.79 g/dl (95% CI: 3.35, 4.23). We could not directly compare our study results with other published studies or

articles as there were differences in inclusion-exclusion criteria, allowance made for iron store repletion, target Haemoglobin level, and time of endline Haemoglobin measurement [7,8,9,10,11,12]. Nonetheless, our finding is well within the range of reported increase in Haemoglobin level [7,8,9,10,11,12].

In this study, the percentage of patients with moderate anaemia became non-anemic after receiving Intravenous iron sucrose was 16.4%. While 15.4% of moderately anemic patients

stayed in the similar category even after receiving Intravenous iron sucrose therapy in recommended dose. The total dose required of iron during pregnancy is approximately 1000 mg (500 mg for the developing foetus and placenta, and 500 mg for red blood cell rise), so the advocated dose of 1000 mg of iron was sufficient to achieve the desired haemoglobin level. It is sufficient and necessary to achieve desired level of Hb to avoid complication of anaemia in pregnancy antenatally, during delivery and during post partum period.

Table 1. Pre-infusion and post infusion haemoglobin level among pregnant women (n=110)

Hb levels	At pre infusion	At post infusion
Normal (> 11 g/dL)		31
Mild (10 – 10.9 g/dL)		62
Moderate (Hb 7-9.9 g/dL)	88	15
Severe (Hb < 7g/dL)	22	2
Total (n)	110	110

Table 2. Mean change in Hb among pregnant women after IVIS therapy (n=110)

Hb levels	At baseline	At endline	Mean change in g/dL (SD), 95% CI
Moderate anemia (n=88)			
Mean Hb in g/dL(SD)	7.5 (0.8)	11.2 (1.15)	3.7 (1.2)
95% CI	7.33, 7.67	10.95, 11.44	3.48, 3.92
Severe anemia (n=22)			
Mean Hb in g/dL(SD)			
95% CI	6.3 (0.6) 6.04, 6.55	10.2 (1.25) 9.38, 10.42	3.9 (1.25) 3.37, 4.42
Mean change in Hb (overall)			
Mean Hb in g/dL(SD)	7.2 (0.7)	10.99 (1.2)	3.79 (1.1)
95% CI	7.07, 7.33	10.77, 11.21	3.35, 4.23
P value - 0.0001			

Table 3. Distribution of anemia with regard to parity

	Mild	Moderate	Severe	Total
Primi	0	34	6	40
2 nd Para	0	25	7	32
Multipara	0	29	9	38
Total	0	88	22	110

Table 4. Rise in Hb level with regard to parity

	Average Hb before IVIS	Mean Hb after IVIS	Rise in HB	Total patients
Primi	8.1	11.79	3.69	40
2 nd Para	7.9	11.68	3.78	32
Multipara	7.2	11.11	3.91	38
Total				110

In India, as per FOGSI and other institutional recommendation the standard dose for prevention of anaemia in pregnancy is 100 days of supplemental oral iron at least. 100 mg of elemental iron plus 500mcg of folic acid is given daily for at least 100 days. Whereas therapeutic dose of 200 mg of elemental iron is required daily to antenatal woman with anaemia (Haemoglobin: 8 to 11 g/dl) for at least 100 days [13]. For the patients with Haemoglobin level 5-8 g/dl i.e. severe anaemia in antenatal patients, parenteral iron preparation is advocated, while transfusion of packed cell volume is advocated for antenatal patients with Haemoglobin level <5 g/dl [13] and after 35 weeks of pregnancy and patient directly come for the labour. There are oral iron and folic acid supplementation to prevent anaemia at term [14]. However, in India, prevalence of anaemia is not declined at that good level despite so many measures. Many reasons are behind the epidemic of anaemia in pregnancy in India like mainly due to poor compliance to oral iron treatment amongst the antenatal woman, linked to perceived and experienced side effects, persistent failure to remember to take iron, inadequate counselling, illogical distribution of iron tablets, and beliefs about adverse effects of consumption of medications during pregnancy. More proximal determinants included difficult access and poor utilization of prenatal health-care services [15,16,17,18]

It has been noted that the effect of oral iron supplementation on Haemoglobin level becomes evident in 3 months of start of supplementation [19]. The change in Haemoglobin level after infusion of Intra venous iron sucrose is therefore likely to become obvious much earlier. So in most of the previous experiences by various authors it is advocated that measurement of haemoglobin should be done when the interval between last dose of intravenous iron sucrose and measurements period is at least 4 weeks [7,8,9,10,11,12]. During the course of normal pregnancy, iron demand increases in second and third trimester partly due to hemodilution and other physiological changes and partly due to foetal and maternal growth so haemoglobin level decreases in second and third trimester if requirements do not met with increased demand [20, 21].

Enrolment of the antenatal subjects was done in second trimester when the Haemoglobin level was in physiologically decreasing phase. Therefore, measurement of haemoglobin was

done at pre infusion level and it was expected to be low. Post infusion end point haemoglobin measurement was done after 4 weeks of last intravenous iron sucrose infusion. There is no control arm in our study. So, we are unable to attribute the fraction of the observed 3.79 g/dl of increase in Haemoglobin level which could be due to the intervention. But, considering the facts from the previous studies, haemoglobin rise without intervention is expected to be minimal.

Blood transfusion was being advised to severely anaemic antenatal patients (Haemoglobin level <7 g/dl) in late trimester. And intra venous iron sucrose was given to those who have not consented for blood transfusion. The average rise in haemoglobin level was 3.9 g/dl and mean post infusion end point haemoglobin was 10.2 g/dl (95% CI: 9.38, 10.42) in antenatal subjects with severe anaemia. As per clinical data low haemoglobin level (<9 gm/dl) is linked with adverse maternal and foetal outcome [2]. Thus, even though proportion of severely anaemic antenatal patients to become non anaemic was only 22.7%, but mean Haemoglobin level achieved post infusion was expected to improve maternal and foetal outcome many fold.

It is recommended to have uniform guideline for public health programme as it has to be implemented over large and diverse geographical area through semi skilled staff. So a uniform dose of 1000 mg intravenous iron sucrose total is recommended for therapeutic usage in antenatal patients with moderate to severe anaemia.

We compared outcomes i.e. rise in haemoglobin level in severely anaemic subjects against antenatal patients with moderate anaemia. The mean rise in Haemoglobin level (3.9 vs. 3.7 g/dl), improvement in category of anaemia (95.45 % vs. 88.63%), and rate of increase in Haemoglobin level was higher in antenatal patients with severe anaemia in comparison with moderately anaemic antenatal patients. Current guidelines do not support administration of Intravenous iron sucrose in antenatal patients with severe anaemia. But we conclude here that antenatal patients with severe anaemia got more benefit in terms of haemoglobin rise than antenatal patient with moderate anaemia. The former also get benefit of haemoglobin rise at faster pace. As a public health approach, in conditions where there is scarcity of blood and its products or any non compliance from the patient side there would be safe and faster option of

intravenous iron sucrose therapy should be considered in antenatal patients with severe anaemia.

HemoCue machine was used to measure haemoglobin level in all patients. This machine is valid and technique is reliable. With sensitivity of 0.75, HemoCue method was gold standard and it has also a very good specificity of 1.0 [22-29]. In the past when nationwide survey of haemoglobin measurement was done this technique was being used by scientist [1]. Same technique was used for both pre infusion and at least 4 weeks after last infusion measurement of Haemoglobin level.

Possibility of thalassemia had been ruled out by use of Mantzer Index in all patient and Hb electrophoresis in selected patient if required.

There was history of previous blood transfusion in 6 patients in previous pregnancy.

All the patients were on vegetarian diet.

CONCLUSION

In antenatal women with moderate to severe anaemia the mean rise in Hb level was 3.79 g/dl after IV iron sucrose was given. The difference of amount of haemoglobin rise is seen more in pregnant women with severe anaemia than antenatal women with moderate anaemia. Intravenous iron sucrose should be given in moderate to severe anaemic antenatal patients as second choice where blood transfusion found difficult or any non compliance from the patient side.

CONSENT

As per international standard or university standard, patients' written consent has been collected and preserved by the author(s).

ETHICAL APPROVAL

The Institute Ethics Committee of the Nootan medical college & research centre, Visnagar, Gujarat, India approved the study.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Simone Garzon, Patrizia Maria Cacciato, Camilla Certelli,* Calogero Salvaggio,⁴ Maria Magliarditi⁵, Gianluca Rizzo² Iron Deficiency Anemia in Pregnancy: Novel Approaches for an Old Problem; 2020 Sep;35(5):e166.
2. Maureen P Tigga , Amulya P Debbarma :A comparative study to evaluate oral iron and intravenous iron sucrose for treatment of anemia in pregnancy in a poor socioeconomic region of Northeast India. 2019;32(3):258-261.
3. Partha Haldar,¹ Shashi Kant,¹ Vikas Yadav,² Jitendra Majhi,³ Sumit Malhotra,¹ Ravneet Kaur,¹ Rakesh Kumar,¹ Arvind Kumar Singh,⁴ Siddaiah Archana,⁵ Ayush Lohia,¹ Ramashankar Rath,¹ and Farhad Ahamed: Effect of intravenous iron sucrose on hemoglobin level, when administered in a standard-dose, to anemic pregnant women in rural Northern India. 2018;7(4): 762–768.
4. Gupta A, Rathore AM, Manaktala U, Gupta A, Gupta S. Role of intravenous iron sucrose in correction of anemia in antenatal women with advanced pregnancy. Indian J Hematol Blood Transfus. 2015;31:251–4. [PMC free article] [PubMed] [Google Scholar]
5. Gupta A, Rathore AM, Manaktala U, Gupta A, Gupta S. Role of intravenous iron sucrose in correction of anemia in antenatal women with advanced pregnancy. Indian J Hematol Blood Transfus. 2015;31:251–4. [PMC free article] [PubMed] [Google Scholar]
6. Sharma DC. India still struggles with rural doctor shortages. Lancet. 2015;386:2381–2. [PubMed] [Google Scholar]
7. Stevens GA, Finucane MM, De-Regil LM, et al. Global, regional, and national trends in haemoglobin concentration and prevalence of total and severe anaemia in children and pregnant and non-pregnant women for 1995-2011: A systematic analysis of population-representative data. Lancet Glob Health. 2013;1(1):e16–e25. [PMC free article] [PubMed] [Google Scholar]
8. Patel S, Goyal A, Shrivastava A, Verma R. Safety and efficacy of parenteral iron

- sucrose complex therapy in iron deficiency anemia in antenatal and postnatal women. *Int J Med Sci Public Health*. 2013;2:360–3. [Google Scholar]
9. Guidelines for Control of Iron Deficiency Anaemia. National Iron-plus Initiative. Ministry of Health and Family Welfare. Government of India. 2013. [Last accessed on 2016 Dec 12]. Available:<http://www.nrhm.gov.in/images/pdf/programmes/child-health/guidelines/Control-of-Iron-Deficiency-Anaemia.pdf> .
 10. Mithra P, Unnikrishnan B, Rekha T, Nithin K, Mohan K, Kulkarni V, et al. Compliance with iron-folic acid (IFA) therapy among pregnant women in an urban area of South India. *Afr Health Sci*. 2013;13:880–5. [PMC free article] [PubMed] [Google Scholar]
 11. Shrivastava D, Inamdar S, Bhute S, Singh A. Effectiveness of intravenous iron sucrose in management of iron-deficient anemia of pregnancy at rural hospital set up. *J Obstet Gynaecol India*. 2012;62:154–7. [PMC free article] [PubMed] [Google Scholar]
 12. Dewan B, Philipose N, Balasubramanian A. Assessment of intravenous iron sucrose in the management of anemia in gynecological and obstetrical practice. *J Obstet Gynaecol India*. 2012;62:281–5. [PMC free article] [PubMed] [Google Scholar]
 13. Cançado RD, de Figueiredo PO, Olivato MC, Chiattoni CS. Efficacy and safety of intravenous iron sucrose in treating adults with iron deficiency anemia. *Rev Bras Hematol Hemoter*. 2011;33:439–43. [PMC free article] [PubMed] [Google Scholar]
 14. Cançado R, Lobo C, Friedrich JR. Iron deficiency anemia treatment with parenteral iron. *Rev Bras Hematol Hemoter*. 2010;32(Suppl 2):121–8. [Google Scholar]
 15. Malhotra J. Iron deficiency anemia in India. *FOGSI Focus* 2009; 9–11.
 16. Gonzales GF, Steenland K, Tapia V. Maternal hemoglobin level and fetal outcome at low and high altitudes. *Am J Physiol Regul Integr Comp Physiol*. 2009;297:R1477–85. [PMC free article] [PubMed] [Google Scholar]
 17. Peña-Rosas JP, Viteri FE. Effects and safety of preventive oral iron or iron+folic acid supplementation for women during pregnancy. *Cochrane Database Syst Rev*. 2009;7(4):CD004736. [PubMed] [Google Scholar]
 18. Toteja GS, Singh P, Dhillon BS, et al. Prevalence of anemia among pregnant women and adolescent girls in 16 districts of India. *Food Nutr Bull* 2006;27:311-5. Back to cited text no. 3[PUBMED]
 19. Malagi U, Reddy M, Naik R. Evaluation of national nutritional anaemia control programme in Dharwad (Karnataka) *J Hum Ecol*. 2006;20:279–81. [Google Scholar]
 20. Raja KS, Janjua NB, Khokhar N. Intravenous iron sucrose complex therapy in iron deficiency anemia in the pregnant women. *Rawal Med J*. 2003;28: 40–3.
 21. Bhaskaram P, Balakrishna N, Radhakrishna KV, Krishnaswamy K. Validation of hemoglobin estimation using Hemocue. *Indian J Pediatr*. 2003;70:25–8. [PubMed] [Google Scholar]
 22. The prevalence of anaemia in women: A tabulation of available information. 2nd ed. Geneva: World Health Organization; 1992. World Health Organization. [Google Scholar]
 23. Wali A, Mushtaq A, Nilofer Comparative study: efficacy, safety and compliance of intravenous iron sucrose and intramuscular iron sorbitol in iron deficiency anemia of pregnancy. *J Pak Med Assoc*. 2002;52: 392–395. [PubMed] [Google Scholar]
 24. Bayoumeu F, Subiran-Buisset C, Baka NE, et al. Iron therapy in iron deficiency anaemia in pregnancy: intravenous route versus oral route. *Am J Obstet Gynaecol*. 2002;186:518–522. DOI: 10.1067/mob.2002.121894. [PubMed] [CrossRef] [Google Scholar]
 25. Galloway R, Dusch E, Elder L, Achadi E, Grajeda R, Hurtado E, et al. Women's perceptions of iron deficiency and anemia prevention and control in eight developing countries. *Soc Sci Med*. 2002;55:529–44. [PubMed] [Google Scholar]
 26. Galloway R, McGuire J. Determinants of compliance with iron supplementation: Supplies, side effects, or psychology? *Soc Sci Med*. 1994;39:381–90. [PubMed] [Google Scholar]
 27. Lu ZM, Goldenberg RL, Cliver SP, Cutter G, Blankson M. The relationship between

- maternal hematocrit and pregnancy outcome. *Obstet Gynecol.* 1991;77:190–4. [PubMed] [Google Scholar]
28. Puolakka J, Jänne O, Pakarinen A, Järvinen PA, Vihko R. Serum ferritin as a measure of iron stores during and after normal pregnancy with and without iron supplements. *Acta Obstet Gynecol Scand Suppl.* 1980;95:43–51. [PubMed] [Google Scholar]
29. Paintin DB, Thomson AM, Hytten FE. Iron and the haemoglobin level in pregnancy. *J Obstet Gynecol Br Commonw.* 1966;73: 181–90. [Google Scholar]

© 2022 Rajput et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/82386>